

Title of Invention

**CELLS** 

## DECLARATION (37 CFR 1.63) FOR UTILITY OR DESIGN APPLICATION USING AN APPLICATION DATA SHEET (37 CFR 1.76)

CD56 POSITIVE HUMAN ADULT PANCREATIC ENDOCRINE PROGENITOR

As the below named inventor(s), I/we declare that:				
This declaration is directed to:	·			
	The attached application, or			
	Application No. 10/658,437 , filed on September 8, 2003,			
	as amended on (if applicable);			
I/we believe that I/we am/are the origought;	ginal and first inventor(s) of the subject matter which is claimed and for which a patent is			
I/we have reviewed and understand the contents of the above-identified application, including the claims, as amended by any amendment specifically referred to above;				
I/we acknowledge the duty to disclose to the United States Patent and Trademark Office all information known to me/us to be material to patentability as defined in 37 CFR 1.56, including for continuation-in-part applications, material information which became available between the filing date of the prior application and the national or PCT International filing date of the continuation-in-part application.				
to be true, and further that these	ur own knowledge are true, all statements made herein on information and belief are believed statements were made with the knowledge that willful false statements and the like are to the the true to the true to the true true true to the true true true true true true true tru			
FULL NAME OF INVENTOR(S				
Inventor 1 Wen-Ghih Tsa	ν Λ			
Signature: X	Citizen of: United States			
Inventor 2 Tianli Zheng	Date: X 1-22-04			
Signature:	Citizen of: United States			
Inventor 3 Wei Liu	Date: X 1-22-04			
Signature: X Web	Citizen of: Peoples Republic of China			
Inventor 4	Date:			
Signature:	Citizen of:			
Additional inventors are being	named on additional form(s) attached hereto.			

type a plus sign (+) inside this box

PTO/SB/81 (02-01)
Approved for use through 10/31/2002. OMB 0651-0035
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

## **POWER OF ATTORNEY OR AUTHORIZATION OF AGENT**

10/658,437
September 8, 2003
Tsang et al.
CD56 Positive Human Adult Pancreatic Endocrine Progenitor Cells
1636
Not known
021164-000310US

I hereby appo	oint:	-					CHIEFT THE COME WATER OF COME	10	
☑ Practitione	ers at Cu	stomer Num							
<i>OR</i> ☐ Practitione	er(s) nan	ned below.	<u> </u>			PATEN	20350 nt trademar	K OFFICE	
	,,(o)		lame		Registrat	ion Number			
<del>  -</del>					registration runner				
-									
L_		····· ·							
as my/our attor business in the	rney(s) o United	or agent(s) to States Paten	prosecute the applicat t and Trademark Office	tion identifie e connecte	ed above, and to d therewith.	transact all			
Please change	the cor	respondence	address for the above	-identified a	pplication to:				
☑ The above-	mention	ed Customer	Number						
OR						<b>▶</b>			
Practitioner	rs at Cus	stomer Numb	er						_
Firm or Individual N	Name								
Address									
Address						-			
City				State		ZIP			
Country									
Telephone				Fax					
I am the:									
Applicant	t/Invento	or.							
Assignee	of reco	rd of the enti	e interest. See 37 CF	R 3.71.					
Statemen	t under	37 CFR 3.73	b) is enclosed. (Form	PTO/SB/96	)	· · · · · · · · · · · · · · · · · · ·	<u>.</u>	<u> </u>	
			SIGNATURE of App	olicant or A	ssignee of Re	cord			
Name X	(Kh	HALID .	SAMI						
Signature X		Han	<b>-</b>						
Date X	( 5	ANUARY	22,2004						
			ors or assignees of re one signature is requ			or their repr	resentative	(s) are required.	,
✓ *Total of 1 f				meu, see L	CIUW .				

Burden Hour Statement: This form is estimated to take 3 minutes to complete. Time will vary depending upon the needs of the individual case. Any Comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

PTO/SB/96 (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Attorney Docket No. 021164-000310US

STATEMENT UNI	DER 37 CFR 3.73(b)	
Applicant/Patent Owner: Wen-Ghih Tsang et al.		
Application No./Patent No.: 10/658,437	Filed/Issue Date: September 8, 2003	
Entitled: CD56 Positive Human Adult Pancreatic Endocrine	Progenitor Cells	
AmCyte Inc. a Califo	rnia corporation	
(Name of Assignee) (Type of As	signee, e.g., corporation, partnership, university, government agency, etc.)	
states that it is:		
1.	st; or	
<ol> <li>an assignee of less than the entire right, title ar The extent (by, percentage) of its ownership into</li> </ol>		
in the patent application/patent identified above by virtue of	either:	
A. An assignment from the inventor(s) of the patent appl was recorded in the United States Patent and Tradem or for which a copy thereof is attached.	ication/patent identified above. The assignment hark Office at Reel, Frame,	
OR		
B. A chain of title from the inventor(s), of the patent appl as shown below:	ication/patent identified above, to the current assignee	
1. From:	To :	
The document was recorded in the United States Reel, Frame, or for which a copy the		
2. From:	То :	
The document was recorded in the United States Reel, Frame, or for which a copy the		
3. From:	To :	
The document was recorded in the United States		
Reel, Frame, or for which a copy the	nereof is attached.	
Additional documents in the chain of title are liste	ed on a supplemental sheet.	
☐ Copies of assignments or other documents in the chain	of title are attached.	
[NOTE: A separate copy (i.e., the original assignment do must be submitted to Assignment Division in accordance recorded in the records of the USPTO. See MPEP 302.8	cument or a true copy of the original document) with 37 CFR Part 3, if the assignment is to be	
The undersigned (whose title is supplied below) is authorize	d to act on behalf of the assignee.	
X JANUARY 22, 2004 Date	X KIHALID SAMI	
Date	X Exped or printed name	
X Offam		
// Signature .		
	X VICE PRESIDENT	
	Title	

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Attorney Docket No.: 021164-000310US

## ASSIGNMENT OF PATENT APPLICATION

**JOINT** 

WHEREAS, Wen-Ghih Tsang of 13161 Morrison Street, Sherman Oaks, CA 91423; Tianli Zheng of 11047 Braddock Drive, Culver City, CA 90230; and Wei Liu of 4362 Nestle Avenue, Cypress, CA 90630, hereinafter referred to as "Assignors," are the inventors of the invention described and set forth in the below-identified application for United States Letters Patent:

Title of Invention:

CD56 Positive Human Adult Pancreatic Endocrine

**Progenitor Cells** 

Date(s) of execution of Declaration:

Filing Date:

September 8, 2003

Application No.:

10/658,437; and

WHEREAS, AmCyte Inc., is a corporation of the state of California, located at 2825 Santa Monica Boulevard, #200, Santa Monica, CA 90404, hereinafter referred to as "ASSIGNEE," is desirous of acquiring an interest in the invention and application and in any U.S. Letters Patent and Registrations which may be granted on the same;

For good and valuable consideration, receipt of which is hereby acknowledged by Assignors, Assignors have assigned, and by these presents do assign to Assignee all right, title and interest in and to the invention and application and to all foreign counterparts (including patent, utility model and industrial designs), and in and to any Letters Patent and Registrations which may hereafter be granted on the same in the United States and all countries throughout the world, and to claim the priority from the application as provided by the Paris Convention. The right, title and interest is to be held and enjoyed by Assignee and Assignee's successors and assigns as fully and exclusively as it would have been held and enjoyed by Assignors had this Assignment not been made, for the full term of any Letters Patent and Registrations which may be granted thereon, or of any division, renewal, continuation in whole or in part, substitution, conversion, reissue, prolongation or extension thereof.

Assignors further agree that they will, without charge to Assignee, but at Assignee's expense, (a) cooperate with Assignee in the prosecution of U.S. Patent applications and foreign counterparts on the invention and any improvements, (b) execute, verify, acknowledge and deliver all such further papers, including patent applications and instruments of transfer, and (c) perform such other acts as Assignee lawfully may request to obtain or maintain Letters Patent and Registrations for the invention and improvements in any and all countries, and to vest title thereto in Assignee, or Assignee's successors and assigns.

Not for recordation (being concurrently sent to PTO for recordation by facsimilie)

Assignment Appln. No. 10/658,437 Attorney Docket No.: 021164-000310US Page 2

IN TESTIMONY WHEREOF, Assignors have signed their names on the dates indicated.

Dated: Jan 21, 04	Windstoang
U	Wen-Ghih Tsang
SIGNATURE WITNESSED BY:	
Oliver K. Foellmer	Date: 1/22/04  Date: 1/22/04
(print name)	
(print name)  KHACID SAMI  (print name)	Date: //22/04
(print name)	
Dated: 1-21-04	Tianli Zheng
SIGNATURE WITNESSED BY:	
Oliver K. Foellmer	Date: $1/21/04$ Date: $1/21/04$
Oliver K. Foellmer (print name)	1.1.1
KHALID SAMI	Date: //2//04
(print name)	
Dated: 1-22-04	Wed
	Wei Liu
SIGNATURE WITNESSED BY:	
Oliver K. Foellmer (print name) KHALID SAMI	Date: 1/22/04
(print name)	
	Date: //22/04
(print name)	



Atty. Docket No.	: <u>021164-000310US</u>
Client Reference No.	•

## VERIFIED STATEMENT (DECLARATION) CLAIMING SMALL ENTITY STATUS (37 CFR 1.27) - SMALL BUSINESS CONCERN

Applicant or Patentee: Wen-Ghih Tsang, Tianli Zheng, and Wei Liu Title: CD56 POSITIVE HUMAN ADULT PANCREATIC ENDOCRINE PROGENITOR CELLS
[ ] the specification filed herewith. [X] Application No. 10/658,437 , filed September 8, 2003
I hereby declare that I am:
the owner of the small business concern identified below: an official of the small business concern empowered to act on behalf of the concern identified below:
Name of Small Business Concern: AmCyte Inc. Address of Small Business Concern: 2825 Santa Monica Boulevard, #200, Santa Monica, CA 90404
I hereby declare that the above-identified small business concern qualifies as a "small business concern" as defined in 13 CFR part 121, for purposes of paying reduced fees to the United States Patent and Trademark Office, in that the number of employees of the concern, including those of its affiliates, does not exceed 500 persons. For purposes of this statement, (1) the number of employees of the business concern is the average over the previous fiscal year of the concern of the persons employed on a full-time, part-time or temporary basis during each of the pay periods of the fiscal year, and (2) concerns are affiliates of each other when either, directly or indirectly, one concern controls or has the power to control the other, or a third party or parties controls or has the power to control both.
Further Assignment
[X] I hereby declare that rights under contract or law have been conveyed to and remain with the small business concern identified above with regard to the invention described above.
[ ] Verified statements by all entities to whom rights to the invention have been transferred, or to whom there is an obligation to transfer rights, are attached hereto.
I acknowledge the duty to file, in this application or patent, notification of any change in status resulting in loss of entitlement to small entity status prior to paying, or at the time of paying, the earliest of the issue fee or any maintenance fee due after the date on which status as a small entity is no longer appropriate. (37 CFR 1.27(g)).  I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and
belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application, any patent issuing thereon, or any patent to which this verified statement is directed.
Name of Person Signing: X KHALID SAM I  Title of Person if Other than Owner: X VICE PRESIDENT  Address of Person Signing: 2825 Santa Monica Boulevard, #200, Santa Monica, CA 90404
Signature X Date X JANUARY 22, 2004
60116882 v1